Q-omics provides the consensus-scored NUDT6 profile across patient tissues and cancer cell-line models. NUDT6 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, NUDT6 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, NUDT6 RNA expression shows 19,462 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, KIRC, and UVM as cancer lineages where NUDT6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUDT6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUDT6 survival associations across molecular data types. NUDT6 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUDT6 RNA expression–survival associations across cancer types. High NUDT6 expression shows unfavorable associations in UVM, but favorable associations in KIRP, READ, COAD, SKCM and ACC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for NUDT6 RNA expression.
This table summarizes NUDT6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NUDT6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUDT6 shows lower tumor expression in KIRC, THCA, KICH, KIRP, BRCA and CHOL. The KIRC box plot shows higher NUDT6 RNA expression in normal versus tumor tissue (log2 FC = −0.499, t-test p < 0.001).
This table shows molecular features associated with NUDT6 in patient tissues and cancer cell lines. In patient samples, NUDT6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NUDT6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
